These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Phenol red is a thromboxane A2/prostaglandin H2 receptor antagonist in canine lingual arteries and human platelets. Greenberg SS; Johns A; Kleha J; Xie J; Wang Y; Bianchi J; Conley K J Pharmacol Exp Ther; 1994 Mar; 268(3):1352-61. PubMed ID: 8138950 [TBL] [Abstract][Full Text] [Related]
8. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation. Vezza R; Nenci GG; Gresele P J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121 [TBL] [Abstract][Full Text] [Related]
9. ZD1542, a potent thromboxane A2 synthase inhibitor and receptor antagonist in vitro. Brownlie RP; Brownrigg NJ; Butcher HM; Garcia R; Jessup R; Lee VJ; Tunstall S; Wayne MG Br J Pharmacol; 1993 Dec; 110(4):1600-6. PubMed ID: 8306107 [TBL] [Abstract][Full Text] [Related]
11. Thromboxane A2 accounts for bronchoconstriction but not for platelet sequestration and microvascular albumin exchanges induced by fMLP in the guinea pig lung. Bureau MF; De Clerck F; Lefort J; Arreto CD; Vargaftig BB J Pharmacol Exp Ther; 1992 Feb; 260(2):832-40. PubMed ID: 1738127 [TBL] [Abstract][Full Text] [Related]
12. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist. Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268 [TBL] [Abstract][Full Text] [Related]
13. Agents combining thromboxane receptor antagonism with thromboxane synthase inhibition: [[[2-(1H-imidazol-1-yl)ethylidene]amino]oxy]alkanoic acids. Cozzi P; Giordani A; Menichincheri M; Pillan A; Pinciroli V; Rossi A; Tonani R; Volpi D; Tamburin M; Ferrario R J Med Chem; 1994 Oct; 37(21):3588-604. PubMed ID: 7932586 [TBL] [Abstract][Full Text] [Related]
14. Evidence for human thromboxane receptor heterogeneity using a novel series of 9,11-cyclic carbonate derivatives of prostaglandin F2 alpha. Krauss AH; Woodward DF; Gibson LL; Protzman CE; Williams LS; Burk RM; Gac TS; Roof MB; Abbas F; Marshall K; Senior J Br J Pharmacol; 1996 Mar; 117(6):1171-80. PubMed ID: 8882612 [TBL] [Abstract][Full Text] [Related]
15. Thromboxane A2 synthase inhibition and thromboxane A2 receptor blockade by 2-[(4-cyanophenyl)amino]-3-chloro-1,4-naphthalenedione (NQ-Y15) in rat platelets. Chang TS; Kim HM; Lee KS; Khil LY; Mar WC; Ryu CK; Moon CK Biochem Pharmacol; 1997 Jul; 54(2):259-68. PubMed ID: 9271330 [TBL] [Abstract][Full Text] [Related]
16. Pharmacological profile of BMS 180,291: a potent, long-acting, orally active thromboxane A2/prostaglandin endoperoxide receptor antagonist. Ogletree ML; Harris DN; Schumacher WA; Webb ML; Misra RN J Pharmacol Exp Ther; 1993 Feb; 264(2):570-8. PubMed ID: 8437108 [TBL] [Abstract][Full Text] [Related]
17. Heterogeneity of thromboxane A2 (TP-) receptors: evidence from antagonist but not agonist potency measurements. Tymkewycz PM; Jones RL; Wilson NH; Marr CG Br J Pharmacol; 1991 Mar; 102(3):607-14. PubMed ID: 1364826 [TBL] [Abstract][Full Text] [Related]
18. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets. Watts IS; Wharton KA; White BP; Lumley P Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620 [TBL] [Abstract][Full Text] [Related]
20. Characterization of the thromboxane (TP-) receptor subtype involved in proliferation in cultured vascular smooth muscle cells of rat. Ko FN; Yu SM; Kang YF; Teng CM Br J Pharmacol; 1995 Sep; 116(2):1801-8. PubMed ID: 8528563 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]